Johnson & Johnson (JNJ) Total Debt (2009 - 2026)
Johnson & Johnson (JNJ) posted Total Debt of $49.0 billion for Q2 2026, down 10.82% sequentially from $55.0 billion in Q1 2026, and down 3.4% YoY from $50.8 billion in Q2 2025.
Johnson & Johnson (JNJ) Total Debt (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Total Debt for 18 years, with the latest figure at $49.0 billion in Q2 2026.
- Quarterly Total Debt fell 3.4% year-over-year to $49.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $49.0 billion (down 3.4% YoY) and the FY2025 annual result came in at $47.9 billion, up 24.88% from the prior year.
- Total Debt fell to $49.0 billion in Q2 2026 per JNJ's latest filing, from $55.0 billion in the prior quarter.
- Over five years, Total Debt peaked at $55.0 billion in Q1 2026 and troughed at $29.9 billion in Q4 2023.
- A 5-year average of $41.3 billion and a median of $41.2 billion in 2023 frame the typical range for Total Debt.
- The sharpest annual moves came in 2023 and 2024: Total Debt jumped 59.61% in 2023, then slumped 36.43% in 2024.
- Over 5 years, Total Debt stood at $32.0 billion in 2022, then retreated by 3.83% to $30.8 billion in 2023, then increased by 24.62% to $38.4 billion in 2024, then climbed by 24.88% to $47.9 billion in 2025, then increased by 2.3% to $49.0 billion in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $49.0 billion, $55.0 billion, and $47.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 49.04 Bn |
| Mar 29, 2026 | 54.99 Bn |
| Dec 28, 2025 | 47.93 Bn |
| Sep 28, 2025 | 45.80 Bn |
| Jun 29, 2025 | 50.76 Bn |
| Mar 30, 2025 | 52.25 Bn |
| Dec 29, 2024 | 38.38 Bn |
| Sep 29, 2024 | 35.75 Bn |
| Jun 30, 2024 | 41.49 Bn |
| Mar 31, 2024 | 33.63 Bn |
| Dec 31, 2023 | 30.80 Bn |
| Oct 1, 2023 | 29.92 Bn |
| Jul 2, 2023 | 45.60 Bn |
| Apr 2, 2023 | 52.91 Bn |
| Jan 1, 2023 | 41.19 Bn |
| Oct 2, 2022 | 32.03 Bn |
| Jul 3, 2022 | 32.60 Bn |
| Apr 3, 2022 | 33.15 Bn |
| Jan 2, 2022 | 35.88 Bn |
| Oct 3, 2021 | 33.93 Bn |